Could a diabetes injection curb cannabis cravings? small trial aims to find out

NCT ID NCT07671248

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This 12-week study tests whether a weekly injection of tirzepatide, a drug used for diabetes, combined with motivational therapy can help adults with moderate to severe cannabis use disorder. Fifteen participants will receive escalating doses of tirzepatide along with counseling. The main goals are to see if the treatment is safe and tolerable, and whether it reduces cannabis use. This is a very early proof-of-concept trial, so results are not yet known.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Tirzepatide (a diabetes drug that may reduce cravings) combined with motivational therapy

What this could lead to

If it works, this could point toward a new treatment option for cannabis use disorder by reducing cravings and withdrawal.

What could go wrong

This is a very small early proof-of-concept study with only 15 people, so results may not apply broadly. The drug may cause side effects like nausea or vomiting, and it's not yet known if it actually reduces cannabis use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANNABIS USE DISORDER, MODERATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cannabis dependence follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • MacAnxiety Research Centre

    Hamilton, Ontario, L8S 1B8, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••